Use of iPSC-Derived Smooth Muscle Cells to Model Physiology and Pathology.
Arterioscler Thromb Vasc Biol
; 44(7): 1523-1536, 2024 07.
Article
en En
| MEDLINE
| ID: mdl-38695171
ABSTRACT
The implementation of human induced pluripotent stem cell (hiPSC) models has introduced an additional tool for identifying molecular mechanisms of disease that complement animal models. Patient-derived or CRISPR/Cas9-edited induced pluripotent stem cells differentiated into smooth muscle cells (SMCs) have been leveraged to discover novel mechanisms, screen potential therapeutic strategies, and model in vivo development. The field has evolved over almost 15 years of research using hiPSC-SMCs and has made significant strides toward overcoming initial challenges such as the lineage specificity of SMC phenotypes. However, challenges both specific (eg, the lack of specific markers to thoroughly validate hiPSC-SMCs) and general (eg, a lack of transparency and consensus around methodology in the field) remain. In this review, we highlight the recent successes and remaining challenges of the hiPSC-SMC model.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Diferenciación Celular
/
Miocitos del Músculo Liso
/
Células Madre Pluripotentes Inducidas
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Arterioscler Thromb Vasc Biol
/
Arterioscler. thrombos. vasc. biol
/
Arteriosclerosis, thrombosis vascular biology
Asunto de la revista:
ANGIOLOGIA
Año:
2024
Tipo del documento:
Article